Literature DB >> 8222870

A new model examining intracellular and extracellular activity of amoxicillin, azithromycin, and clarithromycin in infected cells.

F Scaglione1, G Demartini, S Dugnani, F Fraschini.   

Abstract

An in vitro infection model was created using a suspension of macrophages, polymorphonuclear leukocytes, lymphocytes, fibroblasts, and human serum to which pathogen and antibiotic were added. Separate intracellular and extracellular antibiotic concentrations and activity against Staphylococcus aureus and Legionella pneumophila were assessed for three antimicrobial agents: amoxicillin, azithromycin and clarithromycin. Amoxicillin was found almost exclusively in extracellular fluid, where it was active; intracellularly, it was ineffective. Azithromycin, in contrast, was primarily concentrated and active intracellularly, with little activity in extracellular fluid. Clarithromycin was present in both compartments and possessed significant activity both intracellularly and extracellularly.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222870     DOI: 10.1159/000238987

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  12 in total

1.  Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans.

Authors:  R Piccolomini; G Catamo; G Di Bonaventura
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

2.  In vitro activity of clarithromycin against intracellular Helicobacter pylori.

Authors:  R Piccolomini; G Di Bonaventura; C Picciani; F Laterza; J Vecchiet; M Neri
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 3.  Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria.

Authors:  K Hultén; A Almashhrawi; F A El-Zaatari; D Y Graham
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

Review 4.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

5.  Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin.

Authors:  F Scaglione; G Demartini; S Dugnani; M M Arcidiacono; J P Pintucci; F Fraschini
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

Review 6.  Intracellular concentrations of antibacterial agents and related clinical implications.

Authors:  J D Butts
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

7.  In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers.

Authors:  T J Ives; P Manzewitsch; R L Regnery; J D Butts; M Kebede
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

8.  Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection.

Authors:  J D Alder; P J Ewing; A M Nilius; M Mitten; A Tovcimak; A Oleksijew; K Jarvis; L Paige; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

9.  Measurement of cefaclor and amoxicillin-clavulanic acid levels in middle-ear fluid in patients with acute otitis media.

Authors:  F Scaglione; D Caronzolo; J P Pintucci; F Fraschini
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Distribution of systemic clarithromycin to gingiva.

Authors:  Renita C Burrell; John D Walters
Journal:  J Periodontol       Date:  2008-09       Impact factor: 6.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.